The passion of experts. The science of hepatalin. The new way forward in metabolic health.

SciMar Ltd. was founded in 2009 to accelerate the pioneering medical research of Dr. W. Wayne Lautt and his team as they work to validate and unveil the hepatalin* hormone as the foundation of a new paradigm in the prevention, detection, and treatment of type 2 diabetes.

Through the lens of hepatalin, which was first discovered by Dr. Lautt in 1996, SciMar offers new hope to hundreds of millions of people living with conditions related to metabolic dysfunction, including obesity, fatty liver disease, cardiac dysfunction, and other conditions that put quality of life—and life itself—at risk.

From its lab, research clinic, and offices in Manitoba, Canada, SciMar is advancing its research, running clinical trials, and engaging investors and community partners in this transformational, mission-driven enterprise.

Hepatalin in the missing link in a more complete understanding of human well-being.

Mick Lautt

“Our scientific team is moving the research forward every day, further validating the science of hepatalin. The path is clear. SciMar is on the brink of changing global health and delivering extraordinary returns for our investors.”

Chief Executive Officer, Co-Founder, SciMar Ltd.


Dr. W. Wayne Lautt

“I become a scientist because I wanted to make a positive difference in the world. This is a culmination of my life’s work that I know will change the course of human health. I am inspired by the validation and support of the scientific community, and moved by the enthusiasm of investors who want to see this go forward."

Chief Scientific Officer, Co-Founder, SciMar Ltd.
Professor Emeritus, Department of Pharmacology and Therapeutics, University of Manitoba


*In the academic literature prior to 2021, and in SciMar’s earlier materials, hepatalin was known as hepatic insulin-sensitizing substance (the “HISS” hormone).